1. A 29-year-old woman with PNH (paroxysmal nocturnal hemoglobinuria) is started on eculizumab. Her hematologist explains that while the drug blocks the terminal lytic pathway, certain upstream complement functions remain fully preserved. Which of the following complement-mediated processes remains intact in a patient receiving eculizumab?
A) Cleavage of C5 into C5a and C5b by the C5 convertase.
B) Deposition of C3b on pathogen and altered-cell surfaces, providing opsonization for phagocytic clearance — eculizumab acts downstream of C3 and does not affect C3b generation.
C) Assembly of the membrane attack complex (MAC) from C5b, C6, C7, C8, and polymerized C9.
D) Generation of C5a, the principal complement-derived neutrophil chemoattractant and activator.
E) Polymerization of C9 within the MAC pore structure on complement-susceptible erythrocyte membranes.
ANSWER: B
Rationale:
Eculizumab binds C5 and prevents its cleavage into C5a and C5b, thereby blocking all downstream terminal complement events — C5a generation, MAC assembly, and C9 polymerization. Critically, however, eculizumab acts entirely downstream of C3; it has no effect on C3 cleavage, C3b deposition, or opsonization. C3b generation via all three activation pathways (classical, lectin, and alternative) continues unimpeded in eculizumab-treated patients, which is why approximately 30% of PNH patients on anti-C5 therapy develop clinically significant extravascular hemolysis — C3b continues to opsonize PNH erythrocytes for phagocytic removal in the liver and spleen even though intravascular MAC-mediated lysis is prevented. This preserved opsonization function is also why C3 inhibition (pegcetacoplan) addresses residual extravascular hemolysis that anti-C5 therapy cannot.
Option A: Option A is incorrect because eculizumab directly prevents C5 cleavage by the C5 convertase — this is its mechanism of action and is not preserved.
Option C: Option C is incorrect because MAC assembly requires C5b as the nucleating component; since eculizumab blocks C5 cleavage and thus C5b generation, MAC formation is abolished, not preserved.
Option D: Option D is incorrect because C5a is generated from C5 cleavage; eculizumab's blockade of C5 cleavage eliminates C5a production.
Option E: Option E is incorrect because C9 polymerization within the MAC is the terminal lytic step and requires C5b nucleation; eculizumab prevents this by blocking C5 cleavage upstream.
2. A 54-year-old man with GPA (granulomatosis with polyangiitis) — a form of ANCA-associated vasculitis — is treated with avacopan. His physician notes that unlike anti-C5 agents, avacopan has a fundamentally different point of intervention in the complement cascade. Which of the following best describes the pharmacological consequence of avacopan's distinct mechanism compared to eculizumab?
A) Avacopan prevents C5 cleavage more selectively than eculizumab, producing equivalent blockade of both C5a signaling and MAC formation but with a lower rate of meningococcal infection risk due to its oral bioavailability and lower peak drug concentrations.
B) Avacopan inhibits C3 convertase activity upstream of both C5a generation and MAC formation, providing broader complement blockade than anti-C5 agents at the cost of impairing C3b-mediated opsonization of encapsulated bacteria.
C) Avacopan blocks both C5aR1 and C5aR2 simultaneously, providing more complete suppression of C5a-driven inflammation than anti-C5 agents, which cannot distinguish between the two receptor subtypes when blocking C5 cleavage.
D) Avacopan blocks C5aR1 (C5a receptor 1) on neutrophils and macrophages but does not prevent C5 cleavage; C5b is still generated and MAC formation remains intact, which may preserve bactericidal defense against Neisseria meningitidis compared to agents that abolish terminal complement entirely.
E) Avacopan and eculizumab are pharmacologically equivalent at the level of complement inhibition — both prevent C5a-driven neutrophil activation — but avacopan's oral route makes it preferred for outpatient maintenance while eculizumab is reserved for inpatient induction.
ANSWER: D
Rationale:
Avacopan is an oral small-molecule antagonist of C5aR1 (C5a receptor 1, CD88). Its critical mechanistic distinction from eculizumab and ravulizumab is that it acts downstream of C5 cleavage at the receptor level: C5 is still cleaved by the C5 convertase, generating both C5a and C5b. C5b goes on to nucleate MAC assembly normally, so terminal complement lysis remains intact in avacopan-treated patients. Only the inflammatory signaling of C5a through C5aR1 is blocked — neutrophil priming, degranulation, chemotaxis, and reactive oxygen species production are suppressed, interrupting the neutrophil-driven destructive loop in ANCA vasculitis. Because the MAC pathway is preserved, avacopan may carry a lower risk of the catastrophic fulminant meningococcal disease seen with anti-C5 agents, though meningococcal vigilance remains appropriate.
Option A: Option A is incorrect because avacopan does not prevent C5 cleavage at all; it acts at the C5a receptor, not at C5 itself; MAC formation is not blocked.
Option B: Option B is incorrect because avacopan does not inhibit C3 convertase; C3 inhibition is the mechanism of pegcetacoplan; avacopan is a receptor antagonist acting downstream of all convertase activity.
Option C: Option C is incorrect because avacopan selectively antagonizes C5aR1 (CD88); while C5aR2 (C5L2) exists and has partially anti-inflammatory effects, avacopan's clinical mechanism is C5aR1 blockade, and the comparison to anti-C5 agents conflates receptor-level and ligand-level pharmacology.
Option E: Option E is incorrect because avacopan and eculizumab are not pharmacologically equivalent — eculizumab prevents C5 cleavage and abolishes both C5a generation and MAC formation, whereas avacopan allows both while blocking only C5aR1 signaling; their clinical indications are also entirely different.
3. An immunologist is counseling a second-year resident on the dose-dependent pharmacology of IVIG (intravenous immunoglobulin). She explains that the dose used for antibody replacement in immunodeficiency and the dose used for immunomodulation in autoimmune disease differ substantially, because the two dose levels engage different mechanisms. Which of the following best describes this dose-mechanism relationship?
A) Replacement dosing (typically 400 to 600 mg/kg monthly) restores functional antibody levels in patients with primary or secondary antibody deficiency, maintaining trough IgG above 500 to 700 mg/dL; immunomodulatory dosing (typically 1 to 2 g/kg total over 2 to 5 days) achieves the high peak IgG concentrations required for FcRn saturation, Fc-gamma receptor blockade on macrophages, and anti-idiotypic regulation — mechanisms that require concentrations not reached at replacement doses.
B) Replacement dosing and immunomodulatory dosing use the same total IgG dose but differ in infusion rate — faster infusion rates produce immunomodulatory effects through transient viscosity-mediated platelet aggregation, while slower rates provide steady replacement levels without activating the high-peak mechanisms.
C) Replacement dosing engages T-cell co-stimulation blockade by saturating CD28 receptors on autoreactive T cells with exogenous IgG Fc regions, while immunomodulatory dosing at higher concentrations additionally activates FcRn to accelerate catabolism of pathogenic IgG autoantibodies.
D) Both dosing regimens work through the same mechanism — FcRn saturation and accelerated IgG catabolism — but replacement dosing targets only exogenous pathogen-specific antibodies while immunomodulatory dosing also accelerates catabolism of endogenous autoantibodies due to the higher IgG load delivered.
E) Replacement dosing is effective only in patients with complete agammaglobulinemia (IgG below 100 mg/dL), while immunomodulatory dosing is used for partial antibody deficiency; the therapeutic threshold distinguishes which mechanism is engaged based on baseline IgG levels rather than dose administered.
ANSWER: A
Rationale:
IVIG is used at two fundamentally different dose levels that engage distinct mechanisms. In primary antibody deficiency syndromes (common variable immunodeficiency, X-linked agammaglobulinemia) and secondary antibody deficiency (CLL, post-HSCT hypogammaglobulinemia), replacement dosing of 400 to 600 mg/kg monthly restores functional antibody levels sufficient to prevent recurrent bacterial infections; the goal is to maintain serum IgG trough levels above 500 to 700 mg/dL. Immunomodulatory dosing at 1 to 2 g/kg total (given over 2 to 5 days) achieves the very high peak IgG concentrations required to saturate FcRn (accelerating pathogenic autoantibody catabolism), competitively block Fc-gamma receptors on macrophages (preventing opsonized cell phagocytosis, relevant in ITP), and engage anti-idiotypic neutralization; these mechanisms are concentration-dependent and require the substantially higher doses used in GBS, ITP, CIDP, pemphigus vulgaris, and myasthenia gravis crisis.
Option B: Option B is incorrect because the dose-mechanism relationship is driven by total IgG amount and resulting peak concentrations, not by infusion rate; viscosity is an adverse effect of high-dose IVIG, not a mechanism that distinguishes replacement from immunomodulation.
Option C: Option C is incorrect because IVIG does not engage T-cell co-stimulation blockade through CD28; that is the mechanism of abatacept; IVIG has no known direct CD28-binding activity.
Option D: Option D is incorrect because the two dosing regimens do not share the same mechanism at different scales; FcRn saturation and accelerated catabolism require high doses to achieve; replacement dosing is simply insufficient to saturate FcRn.
Option E: Option E is incorrect because replacement dosing is indicated across a range of antibody deficiency states including partial hypogammaglobulinemia, not only complete agammaglobulinemia; baseline IgG level is not the criterion that determines which dose mechanism applies.
4. A hematology fellow is reviewing the pharmacological differences between eculizumab and ravulizumab for a patient with PNH considering a switch. She wants to accurately counsel the patient about what changes and what does not change when switching between these two agents. Which of the following most accurately characterizes the relationship between eculizumab and ravulizumab?
A) Ravulizumab has a broader set of approved indications than eculizumab — in addition to PNH and aHUS, ravulizumab is also approved for ANCA-associated vasculitis because its extended half-life maintains more consistent C5a receptor blockade between doses.
B) Ravulizumab and eculizumab differ in mechanism: eculizumab prevents C5 cleavage while ravulizumab blocks C5aR1 directly, providing equivalent clinical outcomes through complementary pharmacological targets at lower immunosuppressive burden.
C) Ravulizumab and eculizumab share the same mechanism (C5 blockade), the same approved indications (PNH, aHUS, gMG, NMOSD), and the same meningococcal vaccination and antibiotic prophylaxis requirements; the clinically meaningful difference is dosing frequency — every 8 weeks for ravulizumab versus every 2 weeks for eculizumab in adult maintenance.
D) Ravulizumab eliminates the meningococcal vaccination requirement because its extended half-life maintains continuous complement inhibition without trough periods, whereas eculizumab's every-two-week gaps allow brief windows of complement activity sufficient to maintain baseline meningococcal defense.
E) Ravulizumab is preferred over eculizumab in patients with renal impairment because it is eliminated hepatically rather than renally, avoiding accumulation and dose adjustment requirements that complicate eculizumab use in aHUS patients with chronic kidney disease.
ANSWER: C
Rationale:
Ravulizumab was engineered from eculizumab through four amino acid substitutions in the Fc region that increase FcRn affinity and extend plasma half-life from approximately 11 days to approximately 49 to 52 days. The fundamental pharmacology is identical: both agents bind C5 and prevent its cleavage into C5a and C5b, blocking both the C5a inflammatory pathway and MAC formation. Because the mechanism is the same, the indications are identical — PNH, aHUS, gMG (generalized myasthenia gravis with anti-AChR antibodies), and NMOSD (neuromyelitis optica spectrum disorder with anti-AQP4 antibodies). Because the MAC-blocking mechanism is the same, the meningococcal infection risk is equally present for both agents and the same mandatory vaccination (meningococcal ACWY conjugate + MenB) and antibiotic prophylaxis requirements apply. Clinical non-inferiority has been demonstrated in PNH and aHUS. The practical decision between the agents rests on dosing frequency, intravenous access burden, and patient preference.
Option A: Option A is incorrect because ravulizumab and eculizumab have the same approved indications; ravulizumab is not approved for ANCA vasculitis, which is the indication for avacopan.
Option B: Option B is incorrect because both agents share the same mechanism of C5 binding and blockade; ravulizumab does not act at C5aR1 — C5aR1 antagonism is the mechanism of avacopan.
Option D: Option D is incorrect because the meningococcal vaccination requirement applies equally to both agents; there are no trough windows with ravulizumab that restore meaningful complement activity, and even theoretically continuous C5 blockade would not eliminate the vaccination requirement — it is a prophylactic measure, not a gap-filling measure.
Option E: Option E is incorrect because neither eculizumab nor ravulizumab requires renal dose adjustment; the route of elimination for monoclonal antibodies is proteolytic catabolism, not renal filtration; the distinction described is pharmacologically fabricated.
5. A transplant pharmacist is reviewing biologic immunosuppressants with a group of pharmacy students. She emphasizes that abatacept and belatacept share a common structural scaffold — both are CTLA-4-Ig fusion proteins — but have distinct approved indications. Which of the following correctly identifies the approved indication that distinguishes belatacept from abatacept?
A) Belatacept is approved for moderate-to-severe rheumatoid arthritis refractory to methotrexate, while abatacept is approved for prevention of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
B) Belatacept is approved for psoriatic arthritis and ankylosing spondylitis, conditions in which T-cell co-stimulation blockade provides superior outcomes to TNF inhibition due to entheseal CD28+ T-cell predominance, while abatacept is restricted to RA.
C) Belatacept is approved for systemic lupus erythematosus (SLE) with active nephritis, while abatacept is approved for non-renal autoimmune manifestations of SLE; the distinction reflects belatacept's higher CD80/CD86 affinity and its superior ability to suppress T-follicular helper cell-driven lupus nephritis.
D) Belatacept is approved for prevention of acute cellular rejection in liver transplantation, while abatacept is approved for kidney transplantation; the organ-specific indication reflects differences in hepatic versus renal alloimmune T-cell activation thresholds.
E) Belatacept is approved for prophylaxis of organ rejection in kidney transplant recipients, used in combination with basiliximab induction, mycophenolate, and corticosteroids; abatacept is approved for autoimmune diseases including RA, JIA, and PsA, and for prevention of aGVHD in HSCT — neither agent is approved for the other's primary indication.
ANSWER: E
Rationale:
Abatacept and belatacept are both CTLA-4-Ig fusion proteins that block CD80/CD86-CD28 T-cell co-stimulation, but two amino acid substitutions in belatacept (L104E and A29Y) confer approximately 10-fold higher affinity for CD80 and CD86, making it suitable for the more stringent immunosuppressive demands of solid organ transplantation. Belatacept is approved specifically for prophylaxis of organ rejection in kidney transplant recipients, used in combination with basiliximab (anti-CD25 induction), mycophenolate mofetil, and corticosteroids; it is not approved for autoimmune diseases. Abatacept is approved for moderate-to-severe RA (after methotrexate failure), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), and prevention of acute graft-versus-host disease (aGVHD) in hematopoietic stem cell transplant (HSCT); it is not approved for solid organ transplantation. The two agents occupy entirely separate therapeutic niches despite sharing the CTLA-4-Ig structural scaffold.
Option A: Option A is incorrect because it reverses the correct indications — abatacept is approved for RA and aGVHD prevention in HSCT; belatacept is approved for kidney transplantation, not for RA.
Option B: Option B is incorrect because neither abatacept nor belatacept is approved for ankylosing spondylitis; abatacept is approved for PsA, but belatacept's indication is kidney transplantation, not PsA or ankylosing spondylitis.
Option C: Option C is incorrect because neither belatacept nor abatacept is approved for SLE; belimumab and anifrolumab are the approved biologics for SLE.
Option D: Option D is incorrect because belatacept is approved for kidney transplantation, not liver transplantation; no CTLA-4-Ig fusion protein is currently approved for liver transplant rejection prophylaxis.
6. A 58-year-old man with refractory multiple myeloma is started on daratumumab. Two weeks later, the blood bank reports that his pre-transfusion compatibility testing is showing a pan-reactive positive result that is interfering with crossmatch interpretation. Which of the following best explains this finding?
A) Daratumumab contains IgG1 Fc regions that non-specifically opsonize all donor erythrocytes in the crossmatch, triggering complement-dependent cytotoxicity in the test tube and producing false-positive reactions independent of any specific erythrocyte antigen.
B) Daratumumab induces formation of warm autoantibodies against common erythrocyte antigens by depleting regulatory T cells that normally suppress autoreactive B-cell clones targeting erythrocyte surface proteins.
C) Daratumumab activates complement via its IgG1 Fc region and causes in vitro MAC deposition on reagent erythrocytes during testing, producing a pan-reactive direct antiglobulin test result that resolves with complement-inactivated test sera.
D) CD38 is expressed on the surface of normal human erythrocytes; daratumumab bound to erythrocyte CD38 is detected by the anti-human IgG reagent used in the direct antiglobulin test (DAT), producing a pan-reactive positive result that interferes with antibody identification and crossmatch compatibility testing.
E) Daratumumab causes immune-mediated hemolysis of donor erythrocytes by ADCC (antibody-dependent cellular cytotoxicity) in the crossmatch test tube, generating false-positive incompatibility results that resolve when NK-cell-depleted serum is used for testing.
ANSWER: D
Rationale:
CD38 (cluster of differentiation 38) is a transmembrane glycoprotein highly expressed on plasma cells and plasmablasts, which are the therapeutic targets of daratumumab in myeloma. However, CD38 is also expressed at lower levels on the surface of normal human erythrocytes. When daratumumab is present in a patient's serum, it binds CD38 on reagent erythrocytes used in pre-transfusion compatibility testing; the daratumumab-CD38 complex on the erythrocyte surface is then detected by the anti-human IgG Coombs reagent, producing a positive direct antiglobulin test (DAT) result on all reagent red cells tested — a pan-reactive pattern that cannot be resolved using standard antibody identification panels. This interferes with detection of clinically significant alloantibodies that would indicate true incompatibility. Specialized pre-transfusion testing strategies are required, including the use of CD38-null or dithiothreitol (DTT)-treated reagent cells that no longer bind daratumumab, or molecular blood group genotyping to identify compatible units.
Option A: Option A is incorrect because non-specific Fc-mediated complement activation by daratumumab in the crossmatch tube is not the established mechanism; the pan-reactivity is due to specific CD38 binding on erythrocytes, not non-specific IgG opsonization.
Option B: Option B is incorrect because daratumumab does not deplete regulatory T cells; it depletes CD38-expressing plasma cells and NK cells; daratumumab-induced warm autoantibodies through Treg depletion is not a recognized mechanism.
Option C: Option C is incorrect because in vitro complement MAC deposition is not the mechanism of the pan-reactive DAT; the test uses anti-IgG Coombs reagent detecting drug bound to the erythrocyte surface, not complement deposition.
Option E: Option E is incorrect because ADCC in the test tube is not the mechanism of the crossmatch interference; daratumumab's CD38-erythrocyte binding is a direct binding phenomenon detectable at room temperature with anti-human IgG reagent, not an NK cell-dependent cytotoxicity event.
7. A 62-year-old man with multiple myeloma is six cycles into bortezomib-based therapy. He reports progressive numbness and tingling in his feet bilaterally, worse at night, with absent ankle reflexes on examination. His oncologist recognizes this as the characteristic dose-limiting toxicity of bortezomib. Which of the following correctly identifies this toxicity and explains why bortezomib causes it?
A) Bortezomib causes dose-limiting cardiotoxicity — specifically dilated cardiomyopathy — because cardiomyocytes depend heavily on proteasome-mediated clearance of misfolded contractile proteins, and proteasome inhibition leads to sarcomere protein accumulation and myocyte dysfunction.
B) Bortezomib causes dose-limiting peripheral neuropathy, occurring in approximately 30 to 40% of patients and predominantly sensory in character; the mechanism involves proteasome inhibition in dorsal root ganglion neurons, where disruption of protein homeostasis and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling impairs neuronal survival and axonal maintenance.
C) Bortezomib causes dose-limiting hepatotoxicity through accumulation of ubiquitinated proteins in hepatocytes, triggering caspase-mediated apoptosis that is clinically manifested as transaminase elevation and, in severe cases, drug-induced liver failure requiring discontinuation.
D) Bortezomib causes dose-limiting myelosuppression — particularly profound thrombocytopenia — because megakaryocyte differentiation and platelet production require continuous proteasome-mediated degradation of differentiation inhibitors, and proteasome blockade arrests thrombopoiesis.
E) Bortezomib causes dose-limiting pulmonary toxicity through accumulation of misfolded surfactant proteins in type II pneumocytes; proteasome inhibition blocks surfactant protein clearance, causing progressive interstitial lung disease that limits the cumulative dose that can be safely administered.
ANSWER: B
Rationale:
Peripheral neuropathy is the principal dose-limiting toxicity of bortezomib, occurring in approximately 30 to 40% of patients treated for multiple myeloma. It is predominantly sensory — patients report numbness, tingling, burning, and painful dysesthesias in a stocking-glove distribution, with reduced or absent deep tendon reflexes. The mechanism involves proteasome inhibition in dorsal root ganglion (DRG) neurons, which are particularly vulnerable because they are large, metabolically active cells with high protein synthesis rates and limited regenerative capacity; proteasome blockade disrupts protein homeostasis, impairs NF-kappaB signaling (which supports neuronal survival), and triggers apoptotic pathways in DRG neurons and their axons. The recognition of bortezomib neuropathy as dose-limiting drove the development of carfilzomib (an irreversible next-generation proteasome inhibitor with a different active site selectivity profile and substantially lower neuropathy rates) and ixazomib (an oral proteasome inhibitor). Subcutaneous bortezomib administration also has a lower neuropathy rate than intravenous administration.
Option A: Option A is incorrect because bortezomib-associated cardiomyopathy is a recognized but uncommon toxicity; peripheral neuropathy is the characteristic and most prevalent dose-limiting toxicity in clinical practice.
Option C: Option C is incorrect because while hepatotoxicity can occur with bortezomib, it is not the dose-limiting toxicity; liver failure is not the clinical endpoint that limits cumulative dosing.
Option D: Option D is incorrect because thrombocytopenia does occur with bortezomib (due to transient platelet production impairment) but it is typically reversible between cycles and is not the dose-limiting toxicity that leads to discontinuation; peripheral neuropathy, which is cumulative and may be irreversible, is the true dose-limiter.
Option E: Option E is incorrect because bortezomib-associated interstitial lung disease is a rare, idiosyncratic toxicity rather than a dose-dependent, dose-limiting one; pulmonary toxicity does not define the cumulative dose ceiling for bortezomib therapy.
8. A hematologist is discussing treatment options with a 35-year-old woman with PNH who has residual extravascular hemolysis on eculizumab and is interested in switching to pegcetacoplan. The patient asks about the route and frequency of administration compared to her current therapy. Which of the following correctly describes pegcetacoplan's administration compared to eculizumab?
A) Pegcetacoplan is administered subcutaneously twice weekly — in contrast to eculizumab, which requires intravenous infusion every two weeks; the subcutaneous route allows self-administration at home once the patient is trained, while eculizumab infusions require clinic or infusion center visits.
B) Pegcetacoplan is administered as a once-monthly intravenous infusion, similar to ravulizumab, because its polyethylene glycol modification extends the effective complement-inhibitory half-life to approximately 30 days without the FcRn engineering required for ravulizumab's extended dosing interval.
C) Pegcetacoplan is administered as a daily oral capsule, which represents the primary practical advantage over intravenous anti-C5 agents; the oral bioavailability of the pegylated cyclic peptide scaffold was achieved through lipid nanoparticle formulation technology.
D) Pegcetacoplan is administered intravenously every four weeks — twice as frequently as ravulizumab but half as frequently as eculizumab — reflecting its intermediate half-life relative to the two anti-C5 monoclonal antibodies.
E) Pegcetacoplan is administered subcutaneously once weekly, providing a more convenient schedule than eculizumab's biweekly IV infusions; its monoclonal antibody scaffold targeting C3 ensures adequate complement inhibition between weekly doses.
ANSWER: A
Rationale:
Pegcetacoplan is a pegylated (polyethylene glycol-modified) cyclic peptide that binds C3 and C3b with high affinity, inhibiting complement at the central convergence point upstream of all downstream effects. It is administered by subcutaneous injection twice weekly, which represents a practical advantage for many patients over the intravenous infusion requirement of eculizumab (every two weeks) and ravulizumab (every eight weeks). Subcutaneous self-administration at home is feasible once the patient has been trained, avoiding the need for regular clinic or infusion center visits. The twice-weekly frequency reflects the pharmacokinetic profile of the pegylated cyclic peptide scaffold, which has a shorter effective half-life than monoclonal antibody-based complement inhibitors — the PEG modification extends its half-life compared to the unmodified peptide but does not achieve the weeks-long half-life of IgG-based agents.
Option B: Option B is incorrect because pegcetacoplan is not administered monthly by IV infusion; it is subcutaneous twice weekly; a once-monthly IV regimen describes ravulizumab (approximately every 8 weeks), not pegcetacoplan.
Option C: Option C is incorrect because pegcetacoplan is not orally bioavailable; it is a subcutaneous injection; the oral complement inhibitors in PNH are the small-molecule agents iptacopan and danicopan, not pegcetacoplan.
Option D: Option D is incorrect because pegcetacoplan is not an intravenous agent; it is subcutaneous; the IV interval described does not correspond to any approved pegcetacoplan dosing regimen.
Option E: Option E is incorrect because pegcetacoplan is administered twice weekly, not once weekly; and it is not a monoclonal antibody — it is a pegylated cyclic peptide; these are structurally and pharmacologically distinct drug classes.
9. A 27-year-old woman with selective IgA deficiency (serum IgA undetectable) and recurrent sinopulmonary infections is evaluated for IVIG therapy. Her immunologist explains that standard IVIG preparations cannot be used in this patient without additional precautions, and that a specific alternative formulation is required. Which of the following best explains the safety concern and the appropriate management?
A) Patients with selective IgA deficiency cannot mount an effective antibody response to the IgG in standard IVIG preparations, causing rapid immune complex formation and serum-sickness-like reactions; management requires fractionated IVIG that separates IgG subclasses and removes the IgG3 fraction, which has the highest complement-fixing potential.
B) Selective IgA deficiency is associated with concurrent IgG2 subclass deficiency in most patients; standard IVIG preparations are predominantly IgG1 and provide inadequate opsonization for encapsulated bacteria; IgG2-enriched IVIG preparations are required to achieve protective antibody levels.
C) Patients with selective IgA deficiency may have anti-IgA antibodies (IgG or IgE class) directed against IgA present in standard IVIG preparations; administration of IgA-containing IVIG to a sensitized patient can trigger anaphylaxis; IgA-depleted IVIG preparations are available and should be used in this population.
D) Standard IVIG preparations have high osmolality due to their IgA content, and patients with IgA deficiency lack the mucosal transport proteins required to equilibrate osmotic pressure during infusion; IgA-depleted preparations with adjusted osmolality prevent the acute osmotic nephropathy that otherwise occurs in this population.
E) Patients with selective IgA deficiency have compensatory IgM overproduction that cross-reacts with IgG Fc regions in standard IVIG, producing pseudoagglutination of the infused IgG and vascular occlusion; IgA-depleted preparations stabilized with L-proline avoid this reaction by preventing IgM-IgG cross-linking.
ANSWER: C
Rationale:
Selective IgA deficiency is the most common primary immunodeficiency, characterized by near-absent serum and secretory IgA with normal IgG and IgM levels. A clinically important subset of these patients develop anti-IgA antibodies — primarily IgG class but occasionally IgE class — as a result of sensitization through blood transfusions, prior plasma product exposure, or pregnancy. Standard IVIG preparations are derived from pooled donor plasma and contain small but measurable amounts of IgA. When IgA-containing IVIG is administered to a patient with pre-formed anti-IgA antibodies, the antibodies recognize the IgA in the preparation, triggering a systemic hypersensitivity reaction that can range from mild infusion reactions to severe anaphylaxis — the IgE-mediated mechanism being the most clinically dangerous. IgA-depleted IVIG preparations (with IgA content below 0.05 mg/mL) are commercially available and should be used for IgA-deficient patients requiring immunoglobulin therapy. Pre-treatment with antihistamines and corticosteroids does not reliably prevent IgA-mediated anaphylaxis in sensitized patients.
Option A: Option A is incorrect because serum-sickness from IgG3 complement activation is not the recognized safety concern in IgA-deficient patients receiving IVIG; the established risk is anaphylaxis from anti-IgA antibodies reacting with IgA in the preparation.
Option B: Option B is incorrect because concurrent IgG2 subclass deficiency does occur in some IgA-deficient patients, but the primary safety concern requiring formulation change is anti-IgA antibody-mediated anaphylaxis, not IgG subclass composition of the preparation.
Option D: Option D is incorrect because the osmolality concern in IVIG therapy relates to sucrose-stabilized formulations causing osmotic nephropathy, which is unrelated to IgA content or IgA deficiency; there are no IgA-dependent osmotic transport proteins in IgA-deficient patients.
Option E: Option E is incorrect because IgM-IgG cross-linking causing vascular occlusion is a pharmacologically fabricated mechanism not recognized in the clinical literature on IgA-deficient patients receiving IVIG.
10. An oncologist is selecting a BTK (Bruton tyrosine kinase) inhibitor for a 70-year-old man with CLL (chronic lymphocytic leukemia) who has a history of paroxysmal atrial fibrillation managed with a direct oral anticoagulant. The oncologist considers ibrutinib versus acalabrutinib. Which of the following best explains why acalabrutinib is preferred in this clinical setting?
A) Acalabrutinib is a non-covalent (reversible) BTK inhibitor, allowing BTK to recover between doses and maintaining intermittent platelet BTK activity that limits antiplatelet-mediated bleeding risk when co-administered with anticoagulants — unlike ibrutinib, which permanently inactivates platelet BTK.
B) Acalabrutinib has a longer half-life than ibrutinib, allowing once-daily dosing that reduces the peak drug concentrations responsible for atrial fibrillation triggered by ibrutinib's high-concentration kinase inhibition pattern in atrial tissue.
C) Acalabrutinib does not bind cysteine-481 in the BTK active site and therefore avoids all on-target BTK inhibition in cardiac tissue, eliminating both the atrial fibrillation and the platelet dysfunction seen with ibrutinib; its anti-CLL effect is mediated entirely through BTK-independent B-cell receptor signaling suppression.
D) Ibrutinib and acalabrutinib have identical safety profiles in patients with pre-existing atrial fibrillation, but acalabrutinib is preferred because it does not require dose adjustment when co-administered with direct oral anticoagulants, while ibrutinib's CYP3A4 metabolism creates drug-drug interactions that raise anticoagulant levels unpredictably.
E) Acalabrutinib is a second-generation covalent BTK inhibitor with greater BTK selectivity than ibrutinib, causing substantially lower off-target inhibition of ITK (interleukin-2-inducible T-cell kinase) and EGFR (epidermal growth factor receptor); this selectivity reduces the rate of atrial fibrillation and platelet dysfunction compared to ibrutinib, which is particularly important in a patient with pre-existing AF on anticoagulation.
ANSWER: E
Rationale:
Both ibrutinib and acalabrutinib (along with zanubrutinib) are covalent, irreversible BTK inhibitors that form a covalent bond with cysteine-481 in the BTK active site. The key pharmacological difference is selectivity: ibrutinib inhibits multiple additional kinases sharing the cysteine-481 binding motif, most importantly ITK (IL-2-inducible T-cell kinase) and EGFR, which are expressed in cardiac conduction tissue and are involved in atrial electrophysiology; this off-target inhibition is believed to underlie the 10 to 16% rate of atrial fibrillation seen with ibrutinib. Ibrutinib also inhibits platelet BTK more broadly, impairing collagen-induced platelet aggregation and increasing bleeding risk — a compounding concern in a patient on anticoagulation. Acalabrutinib and zanubrutinib were engineered with structural modifications to minimize off-target kinase inhibition; clinical trials demonstrate substantially lower rates of AF and major bleeding with acalabrutinib compared to ibrutinib. In a patient with pre-existing AF on a DOAC (direct oral anticoagulant), the combination of ibrutinib's AF-promoting and antiplatelet effects with anticoagulation creates significant bleeding and arrhythmia risk, making acalabrutinib strongly preferred.
Option A: Option A is incorrect because acalabrutinib is also a covalent (irreversible) BTK inhibitor, not a reversible one; it forms the same type of covalent bond with cysteine-481 as ibrutinib.
Option B: Option B is incorrect because the half-life difference between ibrutinib and acalabrutinib does not account for the AF risk reduction; the mechanism is differential off-target kinase inhibition, not peak concentration; acalabrutinib is actually dosed twice daily due to its shorter half-life.
Option C: Option C is incorrect because acalabrutinib does bind cysteine-481 and does inhibit BTK; its anti-CLL mechanism is BTK-dependent B-cell receptor signaling suppression, not a BTK-independent pathway.
Option D: Option D is incorrect because ibrutinib and acalabrutinib do not have identical safety profiles in patients with AF; the AF and bleeding rates are substantially lower with acalabrutinib; while CYP3A4 interactions are a consideration with ibrutinib, this is not the primary reason for preferring acalabrutinib in this clinical scenario.
11. A hematologist is reviewing the approved roles of newer oral complement inhibitors for PNH with her fellows. She draws a distinction between two agents — danicopan and iptacopan — emphasizing that their approved therapeutic roles in PNH differ fundamentally despite both being oral alternative pathway inhibitors. Which of the following correctly distinguishes the approved role of danicopan from that of iptacopan in PNH?
A) Danicopan is approved as monotherapy for treatment-naive PNH patients with small clone size, while iptacopan is reserved for patients who have previously failed anti-C5 therapy; the distinction reflects danicopan's superior efficacy in early-stage disease and iptacopan's ability to overcome anti-C5 resistance mechanisms.
B) Danicopan is approved as first-line monotherapy for PNH with predominantly extravascular hemolysis, while iptacopan is approved as add-on therapy to eculizumab or ravulizumab for patients with breakthrough intravascular hemolysis on anti-C5 maintenance dosing.
C) Danicopan and iptacopan have identical approved indications in PNH — both are monotherapy alternatives to anti-C5 agents — but differ in molecular target: danicopan inhibits Factor B while iptacopan inhibits Factor D, and the choice between them is guided by complement biomarker profiling.
D) Danicopan is approved as add-on therapy to eculizumab or ravulizumab specifically for PNH patients with clinically significant extravascular hemolysis that persists despite anti-C5 treatment; iptacopan is approved as monotherapy for PNH — it replaces anti-C5 therapy rather than supplementing it.
E) Danicopan is approved for PNH patients who have developed neutralizing anti-drug antibodies to eculizumab, restoring complement inhibition through an alternative pathway mechanism that is not affected by anti-eculizumab antibodies; iptacopan is used when danicopan fails due to Factor D polymorphisms that reduce its binding affinity.
ANSWER: D
Rationale:
Danicopan and iptacopan both target the alternative pathway amplification loop in PNH — danicopan inhibits Factor D (the serine protease that cleaves Factor B) and iptacopan inhibits Factor B (the serine protease component of the C3 convertase) — but their approved therapeutic roles are structurally different. Danicopan is approved as add-on therapy to eculizumab or ravulizumab for patients who have clinically significant extravascular hemolysis that persists despite anti-C5 therapy; it is used in combination with, not instead of, the established anti-C5 agent. Iptacopan, by contrast, is approved as oral monotherapy for PNH — it replaces anti-C5 therapy entirely, and clinical trial data demonstrated superiority over anti-C5 therapy for extravascular hemolysis reduction and hemoglobin improvement. This distinction matters clinically: a patient already on eculizumab with residual extravascular hemolysis might add danicopan as adjunctive therapy or switch entirely to iptacopan monotherapy — the treatment strategy differs between the two approaches.
Option A: Option A is incorrect because danicopan is not approved as monotherapy for treatment-naive PNH; it is specifically an add-on to anti-C5 therapy for residual extravascular hemolysis, and clone size does not determine which agent is used.
Option B: Option B is incorrect because the approved roles are reversed — iptacopan is the monotherapy agent, not danicopan; and breakthrough intravascular hemolysis on anti-C5 maintenance is not the indication for iptacopan.
Option C: Option C is incorrect because danicopan and iptacopan do not have identical approved indications — their therapeutic roles differ (add-on vs. monotherapy); also the molecular targets are transposed — danicopan inhibits Factor D and iptacopan inhibits Factor B.
Option E: Option E is incorrect because anti-drug antibodies to eculizumab are not the approved indication for danicopan; this describes a pharmacologically fabricated use case not established in clinical trials or labeling.
12. A rheumatology resident is testing her knowledge of abatacept indications before a board examination. She wants to identify the complete set of FDA-approved indications for abatacept. Which of the following lists correctly identifies the approved indications for abatacept?
A) Moderate-to-severe rheumatoid arthritis; systemic lupus erythematosus with active nephritis; juvenile idiopathic arthritis; and prevention of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
B) Moderate-to-severe rheumatoid arthritis (after inadequate response to methotrexate); juvenile idiopathic arthritis (JIA); psoriatic arthritis (PsA); and prevention of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT).
C) Moderate-to-severe rheumatoid arthritis; kidney transplant rejection prophylaxis (as an alternative to calcineurin inhibitors); juvenile idiopathic arthritis; and ankylosing spondylitis with inadequate response to NSAIDs.
D) Moderate-to-severe rheumatoid arthritis; Crohn's disease with inadequate response to anti-TNF therapy; psoriatic arthritis; and prevention of acute graft-versus-host disease in hematopoietic stem cell transplantation.
E) Moderate-to-severe rheumatoid arthritis; ANCA-associated vasculitis as a steroid-sparing agent; juvenile idiopathic arthritis; and atopic dermatitis refractory to topical corticosteroids — all conditions characterized by T-cell co-stimulation-driven pathology.
ANSWER: B
Rationale:
Abatacept is a CTLA-4-Ig fusion protein approved for four indications: (1) moderate-to-severe rheumatoid arthritis (RA) in adults with inadequate response to one or more DMARDs (disease-modifying antirheumatic drugs) including methotrexate or TNF inhibitors, where it can be used as monotherapy or in combination with non-biologic DMARDs; (2) juvenile idiopathic arthritis (JIA) in patients two years of age and older with moderately to severely active polyarticular JIA; (3) psoriatic arthritis (PsA) in adults; and (4) prevention of acute graft-versus-host disease (aGVHD) in adults and pediatric patients two years and older undergoing hematopoietic stem cell transplantation from a matched or one-allele mismatched unrelated donor, in combination with a calcineurin inhibitor and methotrexate. Abatacept is not approved for SLE, kidney transplantation, Crohn's disease, ankylosing spondylitis, ANCA vasculitis, or atopic dermatitis.
Option A: Option A is incorrect because SLE is not an approved indication for abatacept; belimumab and anifrolumab are the approved biologics for SLE; abatacept's approved SLE investigation is ongoing but not established.
Option C: Option C is incorrect because kidney transplant rejection prophylaxis is the indication for belatacept, not abatacept; ankylosing spondylitis is also not an approved abatacept indication.
Option D: Option D is incorrect because Crohn's disease is not an approved indication for abatacept; inflammatory bowel disease biologics include anti-TNF agents, vedolizumab, ustekinumab, and risankizumab — not abatacept.
Option E: Option E is incorrect because ANCA-associated vasculitis is approved for avacopan (and rituximab-based regimens), not abatacept; atopic dermatitis is the indication for dupilumab, not abatacept.
13. An immunologist is asked by a patient with common variable immunodeficiency (CVID) — a primary antibody deficiency syndrome — whether she could switch from monthly IVIG infusions to subcutaneous immunoglobulin (SCIG) injections she could administer at home. A colleague with Guillain-Barré syndrome (GBS) — an acute inflammatory demyelinating polyneuropathy — asks the same question. Which of the following correctly explains how the answer differs between these two patients?
A) Both patients are equally suitable for SCIG; the subcutaneous route is equivalent to intravenous delivery for both replacement and immunomodulatory indications because total IgG exposure over time is what determines efficacy in both settings, regardless of peak concentration achieved.
B) The CVID patient cannot use SCIG because subcutaneous absorption is too variable in immunodeficient patients to maintain reliable trough IgG levels; the GBS patient is the better candidate for SCIG because the lower infusion rate reduces the thromboembolic risk associated with high-dose intravenous IVIG.
C) Neither patient is suitable for SCIG — SCIG is approved only for pediatric antibody deficiency syndromes; adult patients with CVID require intravenous delivery for adequate IgG distribution, and adult GBS patients require the rapid high-peak concentrations achievable only with intravenous infusion.
D) SCIG is an appropriate alternative to IVIG for the CVID patient — providing steadier IgG levels with fewer systemic reactions and allowing home self-administration — but cannot be used for the GBS patient; high-dose immunomodulatory indications such as GBS and ITP require the high peak IgG concentrations achievable only with intravenous delivery, which the subcutaneous route cannot reproduce.
E) SCIG is preferred over IVIG for both patients because its slower absorption avoids the high peak IgG levels responsible for thromboembolic adverse events; the immunomodulatory effect in GBS is enhanced by the sustained lower-level IgG exposure produced by SCIG's pharmacokinetic profile.
ANSWER: D
Rationale:
SCIG (subcutaneous immunoglobulin) and IVIG are both composed of polyspecific pooled IgG but differ pharmacokinetically in a clinically important way. SCIG is administered subcutaneously — typically weekly or biweekly — and produces more stable, steady-state serum IgG levels without the high peaks of monthly IVIG infusions; this is advantageous in replacement therapy for antibody deficiency states (CVID, XLA, hypogammaglobulinemia) where the goal is to maintain a consistent protective IgG trough level. SCIG also produces fewer systemic infusion reactions than IVIG because the gradual subcutaneous absorption avoids the high peak IgG concentrations that trigger systemic symptoms, and home self-administration is a practical advantage. However, SCIG cannot substitute for IVIG in high-dose immunomodulatory indications such as GBS, ITP, dermatomyositis, or myasthenia gravis crisis. The therapeutic mechanisms in these diseases — FcRn saturation with accelerated autoantibody catabolism and Fc-gamma receptor blockade on macrophages — require the very high peak serum IgG concentrations (1 to 2 g/kg delivered over 2 to 5 days) achievable only with intravenous infusion; the subcutaneous route's slower absorption does not generate the peak concentrations required for these mechanisms to operate.
Option A: Option A is incorrect because the two indications are not equivalent for SCIG; high-dose immunomodulatory effects are concentration-dependent and require IV delivery, while replacement is not peak-concentration-dependent.
Option B: Option B is incorrect because SCIG is appropriate for CVID (not contraindicated); the variability of subcutaneous absorption is manageable and SCIG is FDA-approved for adult immunodeficiency replacement; the claim about GBS thromboembolic risk reduction is also not the reason SCIG is inappropriate for GBS.
Option C: Option C is incorrect because SCIG is approved for adult antibody deficiency, not only pediatric patients; the restriction on SCIG is specifically for immunomodulatory indications, not adult use.
Option E: Option E is incorrect because SCIG cannot replace IVIG for GBS; sustained lower-level IgG exposure does not achieve the FcRn saturation and Fc-gamma receptor blockade required for immunomodulation; this option fabricates a pharmacokinetic advantage that does not exist clinically.
14. A 38-year-old woman with PNH has been on eculizumab for four years. Despite adequate intravascular hemolysis control, she has persistent anemia (hemoglobin 9.1 g/dL) from extravascular hemolysis and is asking about oral treatment options. Her hematologist explains that one newly approved oral agent can replace eculizumab entirely rather than being added to it, and that trials showed it outperformed anti-C5 therapy on the primary endpoint of hemoglobin response. Which of the following correctly identifies this agent and its approved role?
A) Iptacopan — an oral Factor B inhibitor that selectively blocks alternative pathway amplification — is approved as monotherapy for PNH in adults; clinical trials demonstrated superiority over anti-C5 therapy for hemoglobin improvement, and it replaces rather than supplements anti-C5 agents, offering a fully oral treatment strategy.
B) Danicopan — an oral Factor D inhibitor — is approved as monotherapy for PNH and demonstrated hemoglobin superiority over eculizumab in the pivotal phase 3 trial; patients switching from eculizumab to danicopan monotherapy showed the greatest hemoglobin gains in those with large clone size and high baseline LDH.
C) Avacopan — an oral C5aR1 antagonist — is approved as monotherapy for PNH as an alternative to intravenous anti-C5 therapy; its oral bioavailability and preserved MAC formation provide both practical convenience and a lower meningococcal infection risk profile compared to eculizumab monotherapy.
D) Pegcetacoplan — approved as a subcutaneous monotherapy — is superior to anti-C5 agents because it targets Factor B specifically within the alternative pathway while leaving classical and lectin pathway opsonization fully intact, providing more targeted complement inhibition with fewer infection-related adverse effects.
E) Zanubrutinib — a selective oral BTK inhibitor — is approved as complement-targeted monotherapy for PNH because BTK signaling downstream of the C5a receptor drives the macrophage-mediated extravascular hemolysis; zanubrutinib's BTK blockade interrupts this pathway without requiring complement inhibition at the protein level.
ANSWER: A
Rationale:
Iptacopan is an oral small-molecule inhibitor of Factor B, which is the serine protease component of the alternative pathway C3 convertase (C3bBb); by inhibiting Factor B, iptacopan prevents alternative pathway amplification — the dominant amplification loop driving complement activation in PNH — while leaving the classical and lectin pathways intact, preserving a broader range of innate immune defense. Iptacopan is approved as monotherapy for PNH, replacing anti-C5 therapy rather than supplementing it. In the pivotal phase 3 APPLY-PNH trial in patients previously on anti-C5 therapy, iptacopan monotherapy demonstrated superiority over continued anti-C5 therapy for the primary endpoint of hemoglobin improvement of at least 2 g/dL or hemoglobin normalization (≥12 g/dL), achieved in approximately 82% of iptacopan-treated patients versus 2% of anti-C5 continuers. This outcome reflects iptacopan's ability to address both intravascular and extravascular hemolysis by preventing C3b deposition upstream.
Option B: Option B is incorrect because danicopan is approved as add-on therapy to anti-C5, not as monotherapy; it has not been approved to replace eculizumab entirely.
Option C: Option C is incorrect because avacopan is approved for ANCA-associated vasculitis, not for PNH; C5aR1 antagonism does not address the C3b opsonization-driven extravascular hemolysis that defines PNH residual disease.
Option D: Option D is incorrect because pegcetacoplan is a C3 inhibitor (not a Factor B inhibitor), is administered subcutaneously (not orally), and does not selectively target only the alternative pathway — C3 inhibition affects all three pathways.
Option E: Option E is incorrect because zanubrutinib is a BTK inhibitor approved for B-cell malignancies; BTK signaling is not the mechanism of extravascular hemolysis in PNH, which is driven by C3b opsonization and reticuloendothelial phagocytosis, not BTK-dependent macrophage activation.
15. A fellow preparing to counsel a patient about iptacopan and danicopan wants to precisely describe the molecular step each agent targets within the alternative pathway amplification loop. Which of the following correctly identifies the sequential steps of alternative pathway C3 convertase assembly and the specific molecular targets of iptacopan and danicopan respectively?
A) The alternative pathway C3 convertase forms when C3b binds properdin (Factor P), which then recruits Factor D; iptacopan inhibits properdin binding to C3b, while danicopan inhibits Factor D after it is already incorporated into the convertase complex — both agents therefore prevent convertase stabilization rather than assembly.
B) The alternative pathway C3 convertase assembles when MBL (mannose-binding lectin) activates MASP-2 (MBL-associated serine protease 2), which cleaves Factor B into Bb; iptacopan prevents MASP-2 from cleaving Factor B, while danicopan inhibits Bb's catalytic activity within the assembled C3bBb convertase.
C) The alternative pathway C3 convertase (C3bBb) assembles when C3b binds Factor B, forming the proconvertase C3bB; Factor D then cleaves Factor B within this complex into Ba (released) and Bb (the catalytic subunit, retained in C3bBb); iptacopan inhibits Factor B, preventing C3bB proconvertase assembly; danicopan inhibits Factor D, preventing cleavage of Factor B into the active Bb subunit.
D) The alternative pathway C3 convertase forms when Factor D spontaneously cleaves circulating Factor B into Ba and Bb in the fluid phase; Bb then binds C3b on target surfaces to form C3bBb; iptacopan prevents Bb from binding C3b on cell surfaces, while danicopan inhibits the initial fluid-phase Factor D cleavage of Factor B before surface association occurs.
E) Factor B and Factor D form a constitutive serine protease complex in plasma that cleaves C3 directly without requiring prior C3b deposition; iptacopan disrupts Factor B-Factor D binding, while danicopan blocks the catalytic site of this preformed complex — both upstream of the C3b amplification loop and therefore effective in treatment-naive patients before any C3b has accumulated.
ANSWER: C
Rationale:
The alternative pathway operates through a surface-based amplification mechanism. Spontaneous hydrolysis of C3 generates C3(H2O), which initiates the cycle; C3b deposited on target surfaces (or C3(H2O) in the fluid phase) binds Factor B, forming the proconvertase C3bB. Factor D — a constitutively active serine protease circulating at very low plasma concentrations — cleaves Factor B within the C3bB complex, releasing the Ba fragment and retaining Bb (which contains the catalytic serine protease site) as C3bBb, the active alternative pathway C3 convertase. Properdin (Factor P) then stabilizes C3bBb, extending its half-life. Iptacopan inhibits Factor B, preventing it from associating with C3b to form the C3bB proconvertase — no proconvertase means Factor D has no substrate to cleave. Danicopan inhibits Factor D, preventing it from cleaving Factor B within the assembled C3bB complex — the proconvertase forms but cannot be activated. Both agents therefore block C3 convertase generation but at sequential steps.
Option A: Option A is incorrect because properdin stabilizes (does not nucleate) the C3bBb complex after assembly; iptacopan and danicopan do not target properdin; and the sequential steps described are pharmacologically inverted.
Option B: Option B is incorrect because MBL and MASP-2 are components of the lectin pathway, not the alternative pathway; the alternative pathway C3 convertase does not depend on MASP-2 activity.
Option D: Option D is incorrect because Factor D does not spontaneously cleave Factor B in the fluid phase to generate free Bb; cleavage requires Factor B to be bound to C3b first (forming C3bB), making the C3b-Factor B interaction the prerequisite for Factor D activity.
Option E: Option E is incorrect because Factor B and Factor D do not form a constitutive preformed complex that cleaves C3 directly; C3b deposition is required for the amplification cycle to proceed and for Factor D to have its substrate.
16. A 55-year-old woman with giant cell arteritis is maintained on tocilizumab (an anti-IL-6 receptor monoclonal antibody) and presents with three days of fever, productive cough, and hypoxia. Her serum CRP is 3 mg/L (reference range <5 mg/L). Her internist explains that this normal CRP does not exclude serious infection in this patient and orders an alternative biomarker. Which of the following best explains why CRP cannot serve as a reliable infection biomarker in this patient, and which alternative is preferred?
A) Tocilizumab depletes circulating IL-6 protein by binding it at the receptor level, reducing the available IL-6 needed to stimulate hepatic CRP production; procalcitonin is preferred because its synthesis in hepatocytes is stimulated by IL-18 rather than IL-6 and is therefore unaffected by IL-6 receptor blockade.
B) CRP is catabolized by the same hepatic enzyme system (CYP3A4) that metabolizes tocilizumab; competitive inhibition of CRP catabolism by high tocilizumab concentrations reduces apparent serum CRP levels without reflecting actual inflammatory state; procalcitonin is renally cleared and unaffected by this drug-enzyme interaction.
C) Tocilizumab blocks IL-6 receptor signaling but upregulates IL-6 levels through a feedback mechanism; the elevated IL-6 saturates and occupies all available CRP binding sites on hepatocyte membranes, preventing new CRP from entering the circulation; procalcitonin binds different hepatocyte receptors not occupied by the elevated circulating IL-6.
D) In giant cell arteritis, CRP is constitutively elevated by the underlying disease; tocilizumab suppresses it to below the normal range by resolving inflammation, making any infection-driven CRP rise appear as a return to normal rather than an elevation; procalcitonin is preferred because it is not constitutively elevated in giant cell arteritis.
E) IL-6 is the primary inducer of hepatic CRP synthesis; tocilizumab blocks the IL-6 receptor (IL-6R), preventing IL-6 signaling to hepatocytes and suppressing CRP synthesis even in the presence of active infection; procalcitonin (PCT) production is stimulated by bacterial endotoxin, IL-1beta, and TNF through IL-6-independent pathways and remains elevated during bacterial infection despite IL-6R blockade, making it the preferred infection biomarker in tocilizumab-treated patients.
ANSWER: E
Rationale:
CRP synthesis in hepatocytes is driven primarily by IL-6 signaling through the JAK1-STAT3 pathway; IL-6 is the dominant acute-phase response cytokine driving hepatic CRP production in response to infection and inflammation. Tocilizumab and sarilumab block the IL-6 receptor (both membrane-bound and soluble forms), preventing IL-6 signaling to hepatocytes and constitutively suppressing CRP synthesis — regardless of inflammatory or infectious stimulus. A patient on tocilizumab will therefore have a normal or low CRP even during serious bacterial infection, pneumonia, or sepsis, making CRP a dangerously unreliable infection biomarker in this population. Procalcitonin (PCT) is produced by parenchymal cells throughout the body (thyroid C-cells, hepatocytes, and other tissues) in response to bacterial endotoxin (lipopolysaccharide), IL-1beta, and TNF — pathways that are upstream of or independent of IL-6; PCT production is not suppressed by IL-6R blockade and rises normally during bacterial infection in tocilizumab-treated patients, making it the preferred infection biomarker. ESR (erythrocyte sedimentation rate) is also less affected by IL-6R blockade than CRP and may provide supplementary information.
Option A: Option A is incorrect because tocilizumab does not deplete circulating IL-6 protein — it blocks the IL-6 receptor, leaving IL-6 protein circulating at elevated levels (the receptor blockade prevents signaling but does not reduce IL-6 concentration); also, PCT synthesis is not stimulated by IL-18 specifically in this context.
Option B: Option B is incorrect because CRP is a protein and is not metabolized by CYP3A4; competitive hepatic enzyme inhibition is not the mechanism by which tocilizumab suppresses CRP; PCT clearance is not the relevant pharmacological distinction.
Option C: Option C is incorrect because elevated circulating IL-6 (which does occur on tocilizumab due to receptor feedback) does not compete for CRP binding sites on hepatocytes; the suppression is at the level of JAK-STAT3 signaling block, not ligand saturation of CRP membrane receptors.
Option D: Option D is incorrect because while tocilizumab does effectively suppress CRP in giant cell arteritis, the clinical problem described — infection with normal CRP — is not due to constitutive baseline elevation but due to pharmacological suppression of CRP synthesis that persists during acute infection.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.